Partial Response to Nivolumab and Ipilimumab in a Patient With Malignant Pleural Mesothelioma and Pre-Existing Myasthenia Gravis Without Severe Flares or Immune-Related Adverse Events: A Case Report

September 17, 2025 | Comments Off on Partial Response to Nivolumab and Ipilimumab in a Patient With Malignant Pleural Mesothelioma and Pre-Existing Myasthenia Gravis Without Severe Flares or Immune-Related Adverse Events: A Case Report

Respirology Case Reports 2025 August 19 [Link] Mariko Higa, Tomoya Kuda, Yuichiro Ohya, Hidenori Kawasaki Abstract Detailed clinical data on the combination immune checkpoint inhibitor (ICI) therapy in patients with…

Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy

September 16, 2025 | Comments Off on Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy

Immunotherapy 2025 August 20 [Link] Giulia Mazzaschi, Roberto Rosati, Simona D’Agnelli, Roberta Minari, Francesca Trentini, Prisca Tamarozzi, Martina Manini, Martina Zinelli Ronzoni, Alessandra Dodi, Letizia Gnetti, Lorena Bottarelli, Cinzia Azzoni,…

Pemetrexed plus platinum as second-line treatment for patients with pleural mesothelioma treated with nivolumab plus ipilimumab

September 15, 2025 | Comments Off on Pemetrexed plus platinum as second-line treatment for patients with pleural mesothelioma treated with nivolumab plus ipilimumab

Lung Cancer 2025 September [Link] Sawana Ono, Hirokazu Taniguchi, Koji Kuroda, Teppei Hashimoto, Asuka Okada, Yasuhiro Goto, Hidenori Kitai, Yoichi Nakamura, Shinsuke Ogusu, Tetsunari Hase, Takayo Ota 10, Noriyuki Ebi,…

Molecular expression of glycosaminoglycans modifies the plasticity of biphasic mesothelioma in favor of tumor progression

September 12, 2025 | Comments Off on Molecular expression of glycosaminoglycans modifies the plasticity of biphasic mesothelioma in favor of tumor progression

Glycoconjugate Journal 2025 August 13 [Link] Camila Machado Baldavira, Aline Nery Qualiotto, Tabatha Gutierrez Prieto, Sandra de Morais Fernezlian, Aline Assato, Marcelo Balancin, Teresa Takagaki, Alexandre Ab’Saber, Ana Paula Pereira…

Co-Targeting Bcl-xL with Mcl-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma

September 11, 2025 | Comments Off on Co-Targeting Bcl-xL with Mcl-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma

Molecular Cancer Therapeutics 2025 August 14 [Link] R Taylor Ripley, Yuan Xu, Cristian G Medina, Deborah R Surman, Lacey E Dobrolecki, Monica Vilchis, Maheshwari Ramineni, Susan G Hilsenbeck, Yanming Li,…

A Promising Prognostic Indicator for Pleural Mesothelioma: Pan-Immuno-Inflammation Value

September 10, 2025 | Comments Off on A Promising Prognostic Indicator for Pleural Mesothelioma: Pan-Immuno-Inflammation Value

Journal of Clinical Medicine 2025 August 4 [Link] Serkan Yaşar, Feride Yılmaz, Ömer Denizhan Tatar, Hasan Çağrı Yıldırım, Zafer Arık 1, Şuayib Yalçın, Mustafa Erman Abstract Background: Pleural mesothelioma (PM)…

Inhibition of LDHB triggers DNA damage and increases cisplatin sensitivity in pleural mesothelioma

September 9, 2025 | Comments Off on Inhibition of LDHB triggers DNA damage and increases cisplatin sensitivity in pleural mesothelioma

Oncogenesis 2025 August 11 [Link] Yantang Lin, Christelle Dubey, Tereza Losmanova, Samuel Oevgü Yasmin, Jean-Louis Reymond, Ren-Wang Peng, Haibin Deng, Patrick Dorn, Thomas Michael Marti Abstract Pleural mesothelioma (PM) is…

Inhibition of LDHB triggers DNA damage and increases cisplatin sensitivity in pleural mesothelioma

September 8, 2025 | Comments Off on Inhibition of LDHB triggers DNA damage and increases cisplatin sensitivity in pleural mesothelioma

Oncogenesis 2025 August 11 [Link] Yantang Lin, Christelle Dubey, Tereza Losmanova, Samuel Oevgü Yasmin, Jean-Louis Reymond, Ren-Wang Peng, Haibin Deng, Patrick Dorn, Thomas Michael Marti Abstract Pleural mesothelioma (PM) is…

First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study

September 5, 2025 | Comments Off on First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study

Lung Cancer 2025 August 5 [Link] Rajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, Daniel C Christoph 4, Frank Griesinger, Martin Reck, Petra Hoffknecht, Jonas Kuo, Nikolaj Frost, Christian Grohé, Martin…

Single-cell RNA-sequencing as a potential approach for studying intratumor heterogeneity in pleural mesothelioma

September 4, 2025 | Comments Off on Single-cell RNA-sequencing as a potential approach for studying intratumor heterogeneity in pleural mesothelioma

Lung Cancer 2025 August 5 [Link] Ania Alay, Raúl Marín, Elisabet Aliagas, Mireia Gausachs, Max Ruiz-Gil, Ivan Macia, Amaia Ojanguren, Susana Padrones, Eduard Dorca, Jesús Brenes, Ramón Palmero, Víctor Moreno,…

Categories